Reprinted from Guangzhou Development Zone Industrial Fund Investment Group

To thoroughly implement the spirit of the high-quality development meetings at the provincial, municipal, and district levels, and focus on the goal of strengthening the biopharmaceutical industry chain within the district, Guangzhou Development District Industry Fund Investment Group Co., Ltd. (hereinafter referred to as "Guangkai Fund") is continuously exploring new ideas for investment promotion. By leveraging a high-level biopharmaceutical CRO platform, they are jointly discovering and selecting a batch of high-quality pharmaceutical projects to create a new precise and batch-style investment promotion model that introduces one to bring in many and develops one to radiate across an area.

On July 13, Worldstar, the investment promotion team under Guangkai Fund, together with its key introduced company, UnionClin, leveraged its high-level CRO R&D platform resource advantages to invite eight innovative drug companies across the country to visit the Guangzhou Development Zone for a one-day inspection and roadshow event. These companies are all led by high-level talents such as national first prize winners of the Science and Technology Progress Award, experts receiving special allowances from the State Council, and PhDs from top global universities. Their technologies involve fields such as small molecule conjugated drug platforms, targeted IL4R monoclonal antibody drugs, AAV gene therapy delivery technology, GPCR drug development platforms, natural antitumor drug research, and the use of AI for targeted design and development of small molecule drugs. Multiple pipelines have entered clinical stages.

In the morning, Dan Xu (Deputy District Mayor of Huangpu District), Ganwu Liu (Deputy Director of the District Investment Promotion Bureau), Qinze Zheng (Chief Engineer of the District Science and Technology Bureau), Haiou Zhang (Deputy Director of the District Financial Bureau), Xiaoling Liang (Deputy Secretary of the Party Committee of Guangkai Fund), and others had in-depth discussions and exchanges with representatives from nine companies. They introduced the business environment and industrial development status of the Guangzhou Development Zone to the participating company representatives, learned about the companies' settlement needs, and expressed their welcome and support for the visits and settlements of each company. 

In the afternoon, under the guidance of the District Financial Bureau, the "Original Research Innovation for the Future" biomedical investment promotion roadshow, hosted by Guangkai Fund and UnionClin and organized by Worldstar, was successfully held at the Development Zone Financial Services Supermarket. Deputy Director of the District Financial Bureau, Shaocheng Mei, and Deputy Secretary of the Party Committee of Guangkai Fund, Xiaoling Liang, attended the event and delivered speeches. More than 50 experts and representatives from biomedical companies and investment institutions participated in the event.

Shaocheng Mei stated that the biopharmaceutical industry in our district has essentially formed a positive trend of comprehensive layout and full-chain development. Nine biopharmaceutical companies, including UnionClin, are highly aligned with our district's goal of fully promoting high-quality development of the biopharmaceutical industry and building a world-class biopharmaceutical industry cluster.

Shaocheng Mei stated that the biopharmaceutical industry in our district has essentially formed a positive trend of comprehensive layout and full-chain development. Nine biopharmaceutical companies, including UnionClin, are highly aligned with our district's goal of fully promoting high-quality development of the biopharmaceutical industry and building a world-class biopharmaceutical industry cluster.

Focusing on Needs, Promoting Policies

At the meeting, Worldstar introduced the business environment, industrial foundation, and the latest policies of the Guangzhou Development Zone to the participating companies. With sincere services, they assisted each company in settling and planning in the Guangzhou Development Zone, empowering the overall industrial development of the district. 

Original Research and Innovation, Exciting Roadshow

Nine biopharmaceutical companies, including UnionClin, conducted a roadshow, comprehensively showcasing the technical quality, development potential, and market prospects of their projects. The roadshow featured active interactions and a lively atmosphere; representatives from investment institutions showed great interest in the projects. In the one-on-one exchange session after the roadshow, investment institutions, investment promotion teams, and project leaders engaged in in-depth discussions, connecting and negotiating on implementation plans.

All companies expressed that the Guangzhou Development Zone has a strong biopharmaceutical industry foundation, robust policies, and an active capital market. They hope to further explore matters related to settling in the area. "At this gathering in the Guangzhou Development Zone, eight innovative pharmaceutical companies have come with full sincerity, advanced technologies, and plans to establish here. We believe that in this land 'closest to success', each company will certainly turn their implementation plans into reality," said Junlin Wang, Chairman of UnionClin.

By focusing on the introduction of original research pharmaceutical companies and high-level biopharmaceutical talent, this event achieved "precise investment promotion" and "batch docking." It is an important demonstration of Guangkai Fund's continuous innovation in investment promotion ideas, deepening the linkage mechanism between investment promotion and investment, and advancing the production-finance docking cooperation model. In the future, Guangkai Fund will continue to focus on regional development directions, leverage the group's dual resources of investment promotion and investment, tightly grasp key enterprises in the industrial chain for batch excavation, introduce high-quality projects, form strategic fulcrums, and amplify fulcrum effects to leverage a "grand pattern" of high-quality investment promotion, continuously accumulating momentum and empowering high-quality industrial development.